Utilization of ultrasonography to detect developmental dysplasia of the hip: when reality turns selective screening into universal use

Rachel Wilf-Miron1,2*, Jacob Kuinter3,4,5, Ronit Peled6, Asaf Cohen7 and Avi Porath6,7

Abstract

Background: Developmental dysplasia of the hip (DDH) occurs in 3–5 of 1000 live births and is associated with known risk factors. In most countries, formal practice for early detection of DDH entails the combination of risk factor identification and physical examination of the hip, while the golden standard diagnostic instrument is hip ultrasonography (US). This practice is commonly referred to as selective screening. Infants with positive US findings are treated with a Pavlik harness, a dynamic abduction splint.

The objective of our study was to evaluate hip US utilization patterns in Maccabi Healthcare Services (MHS), a large health plan.

Methods: Study population: All MHS members, born between June 2011 and October 2014, who underwent at least one US before the age of 15 months. Study variables: Practice specialty and number of enrolled infants. Positive US result was defined as referral to an abduction splint. Cost was based on Ministry of Health price list. Chi square and correlation coefficients were employed in the statistical analysis.

Results: Of the 115,918 infants born during the study period, 67,491 underwent at least one hip US. Of these, 60.6% were female, mean age at performance: 2.2 months. Of those who underwent US, 625 (0.93%) were treated with a Pavlik harness: 0.24% of the male infants and 1.60% of the female infants (p < 0.001). Analysis of physician practice characteristics revealed that referral to US was significantly higher among pediatricians as compared with general practitioners (60% and 35%, respectively). Practice volume had no influence on referral rate. Direct medical costs of the 107 hip US examinations performed that led to detection of one positive case (treated by Pavlik): US$10,000.

Conclusions: Current pattern of hip US utilization for early detection of DDH resembles universal screening more closely than selective screening. This can inform policy decisions as to whether a stricter selective screening or a formal move to universal screening is appropriate in Israel.

Keywords: Quality of care, Cost, Hip developmental dysplasia, Ultrasonography

* Correspondence: r.w.miron@gmail.com
1The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel
2The School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The term *developmental dysplasia of the hip* (DDH) describes a spectrum of conditions related to the abnormal development of the acetabulum and proximal femur leading to mechanical instability of the hip joint in infants and young children [1]. The prevalence of DDH varies from 1.6 to 28.5 cases per 1000 live births, depending on the definition and the population being studied. Most cases of DDH resolve without treatment in the first few months of life [2]. Bialik et al. suggested that “true DDH” incidence of hips with sonographic DDH that did not progress to normal and needed treatment throughout the 12 months of follow-up, is 5 cases per 1000 children [3]. DDH is more common among females compared with male infants, with a relative risk ratio of 2.54 [4]. The condition is also more common among infants with a positive family history or those experiencing abnormal positioning and/or limited fetal mobility, such as breech position [4, 5]. However, the majority of infants with symptomatic DDH evidence no risk factors: a systematic literature review reveals that, only 10–27% of all infants diagnosed with DDH in a population-based studies have identified risk factors (with the exception of female gender) [6–8].

The American Academy of Pediatrics recommends that all newborns be clinically examined for DDH in the first few days of life and at every health supervision visit until the child walks normally [9]. It should be noted that, neonatologists failed to detect about 50% of unstable hips in the initial examination [10]. In infants older than 3 months, unilateral limited hip abduction had a sensitivity of 69% and a specificity of 54% in the detection of ultrasonographically confirmed DDH [11]. Ultrasonography (US) is the diagnostic tool in infants with abnormal physical examination and in infants with risk factors. Until 4–6 months of age, US is the primary imaging technique used to assess the morphology and stability of the infant hip [12, 13]. At age 2 weeks to 6 months, dislocation or persistent instability are treated in Israel as elsewhere, with abduction devices, the Pavlik harness being most commonly used [14, 15]. Two types of screening can be performed: universal screening, in which all neonates are evaluated, and selective screening, in which only those at high risk are evaluated [16, 17]. Universal screening increases DDH detection, which leads to higher rates of treatment with abduction splinting; however, the universal screening approach may lead to high costs, unnecessary treatment, and increased post-treatment complications of avascular necrosis [18, 19] without, however, reducing the time required to accurately diagnose DDH. One should always bear in mind that late diagnosis increases treatment complexity and risks: In the short term - the need for prolonged hospitalization (accompanied by pain, inconvenience and the interruption of the child’s daily activities) and the risks of general anesthesia for both closed reduction or open reduction; recurrent dislocation and subluxation and osteoarthritis. In the short-term, late diagnosis results in a sevenfold increase in the costs of treatment, compared to early detection and successful management in a Pavlik harness [20]. In the long term – increased risk of osteoarthritis and total hip replacement [21]. When the quality of the clinical examination is high, universal US screening has been found to be unnecessary [22]. The American Academy of Pediatrics thus recommends selective US screening for infants with risk factors (female infants born in the breech position, or those with a positive family history of DDH) or abnormal clinical examination findings [9]. US examinations in infants with clinically detected hip instability have been proven to reduce abduction splinting without increasing the rates of abnormal hip development or surgical treatment [12]. This policy was also found to reduce costs [23]. Yet, despite insufficient clinical evidence regarding US strategies, researchers believe that the optimum strategy is to use physical examinations to screen all neonates for hip dysplasia and use hip US selectively, for infants at high risk for DDH and infants with abnormal physical examination [17, 24]. In this scheme, commonly termed “selective screening”, US serves as a screening tool and a golden standard diagnostic instrument at the same time.

The Israeli Task Force on Health Promotion (last update on 2013) advocates US screening among infants with risk factors and infants with abnormal physical examination [25]. Ministry of Health instructions in Israel clearly state that US should be performed according to clinical indications and not as a universal modality [26]. The Ministry’s list of indications include: Clinical signs of hip joint instability, family history of DDH, breech delivery, oligohydramnios and musculoskeletal abnormalities related to tight intrauterine packing (foot or knee deformities, torticollis). The Israeli Task Force adds twin pregnancy and birth weight smaller than 2.5 kg or larger than 4.0 Kg.

Maccabi Healthcare Services (MHS), the second-largest health plan in Israel, provides primary and secondary community-based services to two million beneficiaries. This takes place under universal health insurance coverage that guarantees a universal “basket of services”, including US for the screening of DDH. Services are provided by MHS throughout the country, with a core staff of 8000 physicians, including 2000 primary-care physicians, 1000 nurses and other health professionals. Physicians are usually self-employed; they engage in 17 million physician–patient encounters annually. Every MHS member is allocated to a primary care physician who acts as his/her case manager. Primary care for infants and children is provided by pediatricians or
general practitioners. In-patient care is purchased by MHS from local medical centers.

Recently, researchers found that 14% [27] and 19% [28] of the newborns were referred to hip US assessment due to clinical signs or risk factors. In the absence of data-based evidence, we hypothesized that screening US in Israel is performed at a higher rate than in other countries performing selective screening. The objectives of our study were: 1) to explore US referral patterns for DDH screening; 2) to study the variation between referral pattern and practice characteristics; and 3) to estimate the economic implications of these patterns.

Methods
Setting and study period
The study was conducted by MHS for the period between June 2011 and October 2014.

Study population
All MHS members born between June 2011 and October 2014 and who had undergone at least one hip US before the age of 15 months.

Data source
MHS is a fully computerized organization. Data on US examinations and Pavlik harness treatments was retrieved from MHS’s computerized billing systems. Our data did not include documentation of the reason for referral (i.e. signs of hip instability or mentioning of risk factors).

Variables in the analysis
1) Volume of primary care practice from which the infant was referred, i.e., number of enrolled infants, aged 0–15 months, during the study period. Practices with less than 50 enrolled children were excluded from the analysis because small volume does not reflect referral patterns: The respective physicians might be new to MHS or in practice for very few hours weekly. 2) Physician’s specialty: general practice or pediatrics; 3) Infant’s gender and age at first US examination; 4) Positive US result, defined as referral for an abduction splint; 5) Cost of hip US, as indicated at the Ministry of Health price list, adjusted to January 2015. Data on indirect costs of hip US, such as cost of transportation to the medical facility or loss of parent’s work days when accompanying the infant to the examination could not be obtained and so were ignored.

Statistical methods
Chi square tests were performed to evaluate differences in infant hip US referrals and practice characteristics. Correlation coefficients were calculated for practice volume and first referrals.

Results
During the study period, 115,918 infants, members of MHS, were born, of which 51.6% were male and 48.4% female. Out of the study population, 67,491 (58.2%) underwent at least one US to detect DDH. Rates of hip US were higher among females than among males (60.6% and 56.0%, respectively; \( p < 0.001 \)). The infants’ mean age at performance of the first hip US was 2.2 months (±1.28), being 2.21 (±1.24) for males and 2.23 months (±1.33) for females (\( p < 0.001 \)). Of those who underwent hip US, 675 infants (0.93%) were diagnosed as positive for DDH and thereafter treated with the Pavlik harness. The proportion of positive DDH infants requiring a harness was higher among females than among males: 1.60% and 0.24% respectively (\( p < 0.001 \)) (Table 1). The 625 infants requiring a harness represent a crude overall treatment rate of 5.39 per 1000 live births.

Among the 487 physicians who referred newborns for hip US and thus included in the analysis, 437 were pediatricians with 110,289 registered infants during the study period; the remaining 50 physicians were general practitioners (GPs) with 5110 registered infants during the same period. The mean practice volume of infants in pediatric and GP clinics was 252 (±185.5) and 100 (±58.5), respectively. The number of infants referred by pediatricians and GPs for hip US was 65,701 and 1790, respectively. Those referrals constituted 59.6% and 35.0% of registered infants in the pediatric and general practices, respectively. US proved positive in 0.92% and 1.06% of referrals in pediatric and general practices, respectively (\( p = 0.631 \)) (Table 1).

Figure 1 demonstrates a positive but weak correlation between volume of practice and referral rate to first hip US (\( r = 0.182; \ p < 0.001 \)).

The cost of each hip US for early detection of DDH, in Israeli prices (NIS), based on the official Ministry of Health price list is NIS 361 (US$ 94). In terms of the health plan, 107 examinations were performed with only one case diagnosed as requiring a Pavlik harness (positive case). Hence, the total cost of detecting one case of DDH during the study period reached NIS 38,627 or US$ 10,016.

Discussion
This study demonstrates high utilization of hip US to detect DDH among Israeli physicians. Our Ministry of Health and local professional associations have clearly recommended the selective screening approach, meaning a referral to US following a positive physical examination or high risk indication. Despite this recommendation, a detailed “gold standard” indicating “appropriate” utilization of sonography in selective screening of infant hip DDH has yet to be clearly defined.
Laborie reported the results of 16 years of implementing the selective US strategy, with findings suggesting that although 14% of all newborns were defined “at risk” and referred to hip US, only 3% of these infants received early treatment [27]. Clarke et al. [28] analyzed a prospective cohort of 107,000 live births and found that whereas 19% were referred to hip US assessment due to clinical signs or risk factors, only 3.8% were diagnosed with dysplasia, a crude overall rate of 7.2 cases per 1000 live births. Over the 20-year-study period, the rate of referrals to hip US increased by 5% annually, although the rate of Pavlik harness treatment remained stable [28].

With respect to practice characterization, our study found that the volume of infants registered in the physician’s practice had little influence on referral patterns. However, pediatricians demonstrated significantly higher referral rates when compared with GPs. We do not have data-based explanation for this finding. In the absence of specific data, we may suggest that practices concerning US utilization may also differ by specialty in other countries.

Our data indicates nearly 60% of the infants born during the study period underwent hip US examination during the first 15 months of life. This rate is three times higher than the cited UK and Norwegian data [27, 28]. The rate of treatment in our study was nonetheless similar to those found in the literature, which may be explained by the low rate (0.93%) of positive findings in

### Table 1: Study population characteristics

| Variable                  | Total          | Male             | Female          | P Value |
|---------------------------|----------------|------------------|-----------------|---------|
| Infants (N = 115,918)     | 115,918        | 59,779 (51.6%)   | 56,139 (48.4%)  | –       |
| Birth cohort              | 115,918        | 59,779 (51.6%)   | 56,139 (48.4%)  | –       |
| Mean age (months)         | 2.2 (±1.28)    | 2.21 (±1.24)     | 2.23 (±1.33)    | <0.001  |
| Initial US*               | 67,491 (58.2%) | 33,472 (56.0%)   | 34,019 (60.6%)  | <0.001  |
| Positive US               | 625 (0.93%)    | 81 (0.24%)       | 544 (1.60%)     | <0.001  |
| Physicians (N = 487)      |                |                  |                 |         |
| General Practitioners (N = 50) | 5110 (4.4%) | 110,289 (95.6%) | –               | –       |
| Pediatricians (N = 437)   |                |                  |                 |         |
| Practice volume           | 100 (±58.5)    | 252 (±185.5)     | –               | –       |
| Mean practice volume      | 1790           | 65,701           | –               | –       |
| Initial referral          | 5.0%           | 59.6%            | <0.001          |         |
| Positive US               | 19 (1.06%)     | 606 (0.92%)      | 0.631           |         |

*US = ultrasonography
which resembles universal screening more closely than
patterns of hip US utilization, demonstrates a pattern
positive results of the hip US.

potential over-treatment and complications due to false
order to accompany the infant; exaggerated anxiety re-
considered are the reduced national productivity levels
thirds of the imaging probably unwarranted. Also to be
imaging for hip examinations in

DDH at a rate close to 60% imposes a considerable
phenomenon is relatively rare.

The frequency of claims regarding misdiagnosis of
DDH in childhood have greatly declined in recent years,
probable due to advances in US technology [29]. In
Israel, very few claims have been filed during the last
20 years (based on unpublished data of Israel’s leading
professional liability insurance provider). In the absence
of data on the incidence of late-detected DDH cases in
Israel, the claim filing data might suggest that this
phenomenon is relatively rare.

Measurement is an essential first step toward encour-
gaging more appropriate use of imaging. US screening for
DDH at a rate close to 60% imposes a considerable
burden in terms of unnecessary direct costs, with two-
thirds of the imaging probably unwarranted. Also to be
considered are the reduced national productivity levels
caused by parents absenting themselves from work in
order to accompany the infant; exaggerated anxiety re-
garding a possible diagnosis of DDH; together with the
potential over-treatment and complications due to false
positive results of the hip US.

This study, the first conducted by MHS to evaluate
patterns of hip US utilization, demonstrates a pattern
which resembles universal screening more closely than
selective screening. This gap between national recom-
men  

dation and the actual practice invites policy makers
to re-evaluate the current situation and decide whether
a stricter selective screening or formal move to universal
screening is appropriate in Israel. Until a formal change
in the national policy (which might take quite a long
time), we suggest a number of steps that might be taken:
refreshment of guidelines in tandem with discussions of
uncertainty and other clinical and organizational issues;
distribution of personal referral patterns among prac-
ticing physicians; and redefinition of referral patterns in
the form of organizational quality measures while setting
annual targets.

Our analysis nevertheless exhibits some limitations: 1) The referral data was retrieved from the MHS billing
system, which allows calculation of rates of performance
but not analysis of the reasons for the referral (e.g., ab-
normal clinical findings or the presence of risk factors);
2) The cost data reflects only the known cost of per-
forming a hip US; other direct costs, such as additional
physician encounters, or indirect costs, such as loss of
productivity, transportation expenses or the long-term
consequences of overuse, are not captured by this
variable.

Conclusions
Current pattern of hip US utilization for early detection
of DDH resembles universal screening more closely than
selective screening. This can inform policy decisions as
to whether a stricter selective screening or a formal
move to universal screening is appropriate in Israel.

Abbreviations
DDH: Developmental dysplasia of the hip; GP: General practicitioner;
MHS: Maccabi Healthcare Services; NIS: New Israeli shekel;
US: Ultrasonography

Acknowledgements
None.

Funding
The authors declare that no funding was obtained for this study.

Availability of data and materials
The raw data supporting our findings is kept in a separate repository and
can be reviewed and replicated. Maccabi will consider favorably requests to
share the data with other researchers. Such requests will have to be
approved by Maccabi Research Committee and comply with accepted
confidentiality rules.

Authors’ contributions
RWM carried out the design of the study. She coordinated and wrote all the
versions of the manuscript; JK contributed to the design of the study and
was involved in drafting and revising the manuscript regarding major issues.
RP has made a substantive intellectual contributions to a published study:
She made very substantial contributions to the analysis and interpretation of
data and was involved in drafting and revising the manuscript for important
intellectual content. AC performed the statistical analysis and was involved in
the interpretation of the data. AP made substantial contributions to conception
and design of the study. He was actively involved in data analysis and
interpretation and was involved in drafting the manuscript or revising it critically.
for important intellectual content. All authors declare that they have given final approval of the version to be published. Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
No formal ethics approval was required for the current study, which was carried out in order to examine compliance with the Ministry of Health guidelines regarding the appropriate utilization of hip ultrasonography. The study was approved by the Chief Medical Officer at the Health Division, Central Administration, Maccabi Healthcare Services.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel.
2. The School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
3. Department of Neonatology, Edmond and Lily Safra Children’s Hospital, Tel Aviv, Israel.
4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
5. Maccabi Healthcare Services, Tel Aviv, Israel.
6. Department of Health Systems Management, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be’er Sheva, Israel.
7. Maccabi Institute for Health Services Research, Maccabi Healthcare Services, Tel Aviv, Israel.

Received: 11 November 2015 Accepted: 8 May 2017
Published online: 05 June 2017

References
1. Sewell MD, Rosenfeld K, Eastwood DM. Clinical Review: Developmental dysplasia of the hip. BMJ. 2009;339:b454.
2. Dezateux C, Rosenfeld K. Developmental dysplasia of the hip. Lancet. 2007;369(9572):1541–52.
3. Bialik V, Bialik GM, Blazer S, Sujov P, Wiener F, Berant MSO. Developmental dysplasia of the hip: a new approach to incidence. Pediatrics. 1999;103(1):93.
4. Ortiz-Neira CL, Paolucci EO, Donnon T. A meta-analysis of common risk factors associated with the diagnosis of developmental dysplasia of the hip in newborns. Eur J Radiol. 2012;81(3):344–51.
5. Committee SMA. Screening for the detection of congenital dislocation of the hip. Arch Dis Child. 1986;61:921–6.
6. Shipman SA, Helfand M, Moyer VA, Yawn BP. Screening for developmental dysplasia of the hip: a systematic literature review for the US preventive services task force. Pediatrics. 2006;117:657–75.
7. Sanghrajka A, Murnaghan CF, Shekeris A, Eastwood DM. Open reduction for developmental dysplasia of the hip: failures of screening or failures of treatment? Ann R Coll Surg Engl. 2013;95(2):113–7.
8. Sink EL, Ricciardi BF, Torre KD, Price CT. Selective ultrasound screening is inadequate to identify patients who present with symptomatic acetabular dysplasia. J Child Orthop. 2014;8(6):451–5.
9. American Academy of Pediatrics. Clinical practice guideline: early detection of developmental dysplasia of the hip. Pediatrics. 2000;105(4):896-905.
10. Rosenberg N, Bialik V, Norman D, Blazer S. The importance of combined clinical and sonographic examination of instability of the neonatal hip. Int Orthop. 1998;22(3):185–8.
11. Choudry Q, Goyal R, Paton RW. Is limitation of hip abduction a useful clinical sign in the diagnosis of developmental dysplasia of the hip? Arch Dis Child. 2013;98(11):862–6.
12. American College of Radiology. ACR Appropriateness Criteria: Developmental dysplasia of the hip-child. Date of origin: 1999. Last review date: 2013. https://acsearch.acr.org/docs/65437/Narrative. Accessed 31 May 2017.
13. Edelman M, Katzman A, Freeman S, Peled E, Bialik V. Treatment of true developmental dysplasia of the hip using Pavlik’s method. J Pediatr Orthop B. 2003;12(4):253–8.
14. Elbourne D, Dezateux C, Arthur R, Clarke NM, Gray A, King A, Quinn A, Gardner F, Russell G. UK collaborative hip trial group. Ultrasoundography in the diagnosis and management of developmental hip dysplasia (UK hip trial): clinical and economic results of a multicentre randomised controlled trial. Lancet. 2002;360(9350):2009–17.
15. Peled E, Bialik V, Katzman A, Edelman M, Norman D. Treatment of Graf’s ultrasound class III and IV hips using Pavlik’s method. Clin Orthop Relat Res. 2008;466(4):825–9.
16. Shorter D, Hong T, Osborn DA. Screening programs for developmental dysplasia of the hip in newborn infants. Cochrane Database Syst Rev. 2011, Issue 9. Art. No.: CD004595. DOI: 10.1002/14651858.CD004595.pub2.
17. Mahan ST, Katz JN, Kim YJ. To screen or not to screen? A decision analysis of the utility of screening for developmental dysplasia of the hip. J Bone Joint Surg. 2009;91(7):1705–19.
18. Cashman JP, Round J, Taylor G, Clarke NM. The natural history of developmental dysplasia of the hip after early supervised treatment in the Pavlik harness. Bone Joint J. 2002;84(4):418–25.
19. Treuvelhula M, Reading IC, Clarke NMP. Failed Pavlik harness treatment for DDH as a risk factor for avascular necrosis. J Pediatr Orthop. 2015;35(2):140–3.
20. Woodacre T, Dhdaval A, Ball T, Edwards C, Cox PJIA. The costs of late detection of developmental dysplasia of the hip. J Child Orthop. 2014;8(4):325–32. doi:10.1007/s11832-014-0599-7.
21. Morin C, Wigart P. And French Society of Pediatric Orthopaedics. Congenital dislocation of the hip, with late diagnosis after 1 year of age: update and management. Orthop Traumatol Surg Res. 2012;98(6):515–8.
22. Holen KJ, Tegnander A, Bredland T, Johansen OJ, Sæther OD, Eik-Nes SH, Terjesen T. Universal or selective screening of the neonatal hip using ultrasound? A prospective, randomized trial of 1,529 newborn infants. Bone Joint J. 2002;84(6):886–90.
23. Gray A, Elbourne D, Dezateux C, King A, Quinn A, Gardner F. Economic evaluation of ultrasoundography in the diagnosis and management of developmental hip dysplasia in the United Kingdom and Ireland. J Bone Joint Surg Am. 2005;87(11):2472–9.
24. Shorter D, Hong T, Osborn DA. Cochrane review: screening programmes for developmental dysplasia of the hip in newborn infants. Evid Based Child Health. 2013;8(1):111–54.
25. Tabenkin H, Lahad A. The Israeli task force on health promotion and preventive medicine: Clinical guidelines. The Israel Association of Family Physicians and the Israeli Medical Association. 2013. (First publication - 2000; revised in 2004, 2008 and 2013). (In Hebrew).
26. Dor M. Identification of hip joint instability in neonates and infants. Instructions of the Ministry of Health, based on the recommendation of the National Council on Pediatrics and Child Health, 2014, Jerusalem. Also available at: http://www.health.gov.il/hozer/mt17_2007.pdf. Accessed 17 Mar 2017. (In Hebrew).
27. Laborie LB, Markstedt TJ, Davidson H, Brudå KR, Aukland SM, Bjørrum JK, Reigstad H, Indrekvam K, Lehmann TG, Engesæter IØ, et al. Selective ultrasound screening for developmental hip dysplasia: Effect on management and late detected cases. A prospective survey during 1991–2006. Pediatr Radiol. 2014;44(4):410–24.
28. Clarke NM, Reading IC, Corbin C, Taylor CC, Bochmann T. Twenty years’ experience of selective secondary ultrasound screening for congenital dislocation of the hip. Arch Dis Child. 2012;97(5):423–9.
29. McBee GN, Donn SM, Mendelson RA, McDonnell WM, Gonzalez JL, Ake JK. Medical diagnoses commonly associated with pediatric malpractice lawsuits in the United States. Pediatrics. 2008;122(6):e1282–6.